
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc. is projected to achieve approximately $32 million in top-line revenue for 2025, with expectations of a substantial increase to $130.4 million in 2026, indicating strong growth potential. The market access situation for the company appears favorable, suggesting the possibility of improved coverage and further revenue enhancements in the near term. Additionally, the robust pipeline of gene therapies aimed at addressing unmet medical needs could provide additional upside to the company's financial forecasts.
Bears say
Abeona Therapeutics Inc faces significant risks that contribute to a negative outlook, particularly regarding the potential slower than anticipated market uptake of its flagship product, pz-cel, in the United States. Additionally, the company may struggle to optimize the value of pz-cel in international markets, compounded by the possibility of setbacks in their earlier-stage pipeline programs, which could further hinder revenue growth. Furthermore, there exists a long-term dilution risk that could adversely affect shareholder value and financial stability.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares